MIRA MIRA Pharmaceuticals, Inc.
$0.55▲ +2.48%
Healthcare
Other
Volume 68.4K
Avg Volume (10D) 106.0K
Key Metrics & Fundamentals
Market Cap
$22.94M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.52 - 1.80
% vs 50 MA
-29.29%
% vs 200 MA
-45.79%
RSI-14
29.6
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.03
Free Cash Flow
-$1.21M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.16M
COGS
–
Operating Exp
$1.16M
Operating Income
-$1.16M
EBIT
-$1.16M
Pretax Income
-$1.21M
Net Income
-$1.21M
EPS (Diluted)
-0.03
Price & Volume History
Loading chart…
Recent News
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
GlobeNewswire · Oct 22, 2026 8:00 AM ET
Modera Launches AI-Powered Platform Mira to Support Tailored Financial Advice for Clients
PR Newswire · Oct 21, 2026 9:00 AM ET
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
GlobeNewswire · Sep 17, 2026 8:30 AM ET
Copper Giant Identifies Thirteen Targets Beyond the Mocoa Resource and Its Interpreted Extensions
CNW Group · Sep 16, 2026 7:30 AM ET
Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard
PR Newswire · Sep 1, 2026 8:04 AM ET
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
GlobeNewswire · Sep 1, 2026 8:00 AM ET
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
Stocktwits · Aug 6, 2026 9:19 AM ET
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
GlobeNewswire · Aug 6, 2026 8:00 AM ET
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
GlobeNewswire · Jul 30, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See MIRA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.